AOCs

Antibody–Oligonucleotide Conjugates Clinical Manufacturing — A New Paradigm Shift of Bio-Conjugates for Therapeutics

Muctarr Sesay, Ph.D.; Natalia Bourguignon, Ph.D.

GBI Biomanufacturing

Asia Manufacturing

APAC Expands Specialized Manufacturing Capabilities Across High-Value Modalities

Pharma's Almanac

ADC Formulation

Controlling Complexity in ADC Formulation Development

Eunbi Iris Cho, Ph.D.

Samsung Biologics

U.S. CDMO Capacity

More Than Capacity: What the Latest U.S. CDMO Expansion Wave Reveals About Specialized Manufacturing Demand

Pharma's Almanac

Roundtable

How is the increasing complexity of modalities reshaping CDMO differentiation and specialization strategies?

Pharma's Almanac

ADCs

Re-Engineering ADCs for Autoimmune and Inflammatory Disease

David Alvaro, Ph.D.

Pharma's Almanac

Conjugation

Why ADC Conjugation Strategy Is Now a CMC Decision

David Alvaro, Ph.D.

Pharma's Almanac

ADC Platform

From mAbs to ADCs: Rethinking the Platform Manufacturing Model

David Alvaro, Ph.D.

Pharma's Almanac

ADC Linkers

Linker Chemistry as the Hidden Determinant of ADC Success

David Alvaro, Ph.D.

Pharma's Almanac

ADC Engineering

Engineering Antibodies for Precision Payload Delivery

David Alvaro, Ph.D.

Pharma's Almanac

Conjugate Payloads

Beyond Cytotoxins: Expanding the Payload Landscape for Antibody-Based Conjugates

David Alvaro, Ph.D.

Pharma's Almanac

ADCs

Accelerating ADC Analytical Method Development Through Platform Innovation

Jaeook Kim, Ph.D.

Samsung Biologics

ADCs

Improved Efficacy and Safety Driving Resurging Interest in ADCs

Cynthia A. Challener, Ph.D.

Pharma's Almanac

Ovarian Cancer

Ovarian Cancer at an Inflection Point: Quantifying the Burden, Closing Gaps, and Accelerating Next-Generation Therapies

David Alvaro, Ph.D.

Pharma's Almanac

Biotechs

Next-Gen Biopharma: The Startups Leading the Charge

Cynthia A. Challener, Ph.D.

Pharma's Almanac

Biomanufacturing

Organoids, ADCs, and More on the Horizon at Samsung Biologics

Kevin Sharp

Samsung Biologics

Continuous

Novel Integration of Process Analytical Technologies for Continuous Biomanufacturing

Edita Botonjic-Sehic, Ph.D.

Recipharm Advanced Bio

Next-Gen Biologics

What do you see as the next big modality in biologics, and what factors are driving innovation in this space?

Pharma's Almanac

Radioconjugates

Rising Interest in Radioconjugate Therapies

Cynthia A. Challener, Ph.D.

Pharma's Almanac